More Than 25% Of Indian TB Patients Resistant To At Least One Drug, National Survey Shows

Economic Times: World TB Day: Over 25% TB patients in India are resistant to at least one anti-TB drug
“More than a quarter of tuberculosis patients in India are resistant to at least one commonly used drug to treat the disease, stated a new national survey conducted to understand the prevalence of drug-resistance among TB patients in the country. The survey reported high treatment failure and death rates of multi-drug resistant TB patients than the global level. The study, which places particular focus on multi-drug resistant TB among both new and previously treated patients, stated that a high number of MDR-TB patients were resistant to a class of antibiotics known as fluoroquinolone…” (Raghavan, 3/24).

The Hindu: A fourth of Indian TB patients are drug resistant
“…Among the 4,958 patients on whom drug susceptibility testing (DST) was conducted (necessary to find out if a person has drug-resistant TB), 28% had resistance to one or the other anti-TB drug, while 6.19% had multi-drug resistant (MDR) TB. … While this is the largest study of its kind, the survey does not reveal the national burden of DR-TB as it does not include data from patients being treated in the private sector…” (Krishnan, 3/25).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.